Outcome | Results | Absolute effect estimates | Quality of evidence | Plain language summary | |
6-Month ADCT | 3-Month ADCT | ||||
DFS (overall study population) | HR: 1.17 (80% CI, 1.05 to 1.31) (95% CI, 0.99 to 1.38) (3273 patients in four studies*) Follow-up: 5 years | 161 per 1000 | 186 per 1000 | Low¶ | 3-Month ADCT probably has little or no effect on DFS compared with 6-month ADCT |
Difference: 25 more per 1000 (95% CI, 7 more to 44 more) | |||||
DFS (CAPOX) | HR: 1.02 (80% CI, 0.88 to 1.17) (95% CI, 0.83 to 1.28) (2019 patients in four studies*) Follow-up: 5 years | 159 per 1000 | 162 per 1000 | Low¶ | 3-month ADCT probably has little or no effect on DFS (CAPOX) compared with 6-month ADCT |
Difference: 3 more per 1000 (95% CI, 18 fewer to 24 more) | |||||
DFS (FOLFOX) | HR: 1.41 (80% CI, 1.18 to 1.68) (95% CI, 1.08 to 1.84) (1254 patients in four studies*) Follow-up: 5 years | 150 per 1000 | 205 per 1000 | Low¶ | 3-month ADCT probably worsens DFS (FOLFOX) compared with 6-month ADCT |
Difference: 55 more per 1000 (95% CI, 25 more to 89 more) | |||||
Grade ≥2 peripheral neuropathy | RR: 0.36 (95% CI, 0.31 to 0.42) (3273 patients in four studies*) Follow-up during treatment | 360 per 1000 | 130 per 1000 | Moderate | Patients experience significantly less peripheral neuropathy with 3 months of ADCT compared with 6 months of ADCT |
Difference: 230 fewer per 1000 (95% CI, 248 fewer to 209 fewer) |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟